Genetics of Breast and Ovarian Cancer - National Cancer Institute

Table 6. Uptake of Risk-Reducing Mastectomy (RRM) and/or Breast Screening (Mammography and/or Breast MRI)

Study Citation Study Population RRM Breast Screening Mammography and/or Breast MRI Length of Follow-up Comments

United States

[162] Carriers (N = 22)^a Carriers 54% Not applicable 12 mo All participants had newly diagnosed breast cancer.

Noncarriers (N = 127)^a Noncarriers 25%

[163] Carriers (N = 194)^{a, b} Carriers 14.9% Mammography Mean 24.8 mo; range 1.6–66.0 mo Women opting for RRM were younger and had more family members with breast or ovarian cancer.

Carriers 93.4%

MRI

Not evaluated

[164] Carriers (N = 37)^a Carriers 0% Mammography 24 mo

Carriers 57%

Noncarriers 49%

Noncarriers (N = 92)^a Noncarriers 0% Declined test 20%

Declined testing (N = 15)^a MRI

Not evaluated

[124] Carriers (N = 84)^a Carriers 3% Mammography 12 mo Screening adherence in carriers was unchanged from baseline.

Carriers 68%

Noncarriers (N = 83)^a Noncarriers 0% Noncarriers 44%

Declined test 54%

Declined testing (N = 49)^a MRI

Not evaluated

International

[165] Carriers (N = 70)^a Carriers 11% Mammography 3 y

Carriers 89%

MRI

Not evaluated

[166] Carriers (N = 34)^a Carriers 9% Mammography 12 mo

Carriers 95%

Noncarriers 60%

Noncarriers (N = 34)^a MRI

Not evaluated

[167] Carriers (N = 26)^a Carriers 54% Not applicable 12 mo Carriers opting for RRM had higher levels of general and cancer-related distress.

Noncarriers (N = 37)^a Noncarriers 0%

[168] Carriers (N = 68)^b Carriers 51% Carriers 49% Median 21 mo; range 10–61 mo Carriers opting for RRM tended to be younger.

Data based on specific method(s) not reported.

[169] Carriers (N = 517)^a Carriers 30% (unaffected) Not applicable Not provided Women with a sister with breast cancer were more likely to have an RRM.

249 participants had a personal history of breast cancer.

[170] Carriers (N = 2,677)^a Carriers 18% (unaffected) Mammography 3.9 y; range 1.5–10.3 y Large differences in uptake of risk management options by country.

Carriers 87%

MRI

Carriers 31%

[171] Carriers (N = 537)^c Carriers 21% Not Applicable Minimum 6 mo; median 36 mo

^aSelf-report as data source.

^bMedical records as data source.

^cData source not specified.

MRI = magnetic resonance imaging.

References

Lerman C, Hughes C, Croyle RT, et al.: Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 31 (1): 75-80, 2000. [PUBMED Abstract]
Phillips KA, Jenkins MA, Lindeman GJ, et al.: Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clin Genet 70 (3): 198-206, 2006. [PUBMED Abstract]
Claes E, Evers-Kiebooms G, Decruyenaere M, et al.: Surveillance behavior and prophylactic surgery after predictive testing for hereditary breast/ovarian cancer. Behav Med 31 (3): 93-105, 2005. [PUBMED Abstract]
Lodder LN, Frets PG, Trijsburg RW, et al.: One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 73 (2): 97-112, 2002. [PUBMED Abstract]
Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al.: Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 355 (9220): 2015-20, 2000. [PUBMED Abstract]
Metcalfe KA, Foulkes WD, Kim-Sing C, et al.: Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin Genet 73 (5): 474-9, 2008. [PUBMED Abstract]
Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, et al.: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 122 (9): 2017-22, 2008. [PUBMED Abstract]
Friebel TM, Domchek SM, Neuhausen SL, et al.: Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers. Clin Breast Cancer 7 (11): 875-82, 2007. [PUBMED Abstract]
Tercyak KP, Peshkin BN, Brogan BM, et al.: Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol 25 (3): 285-91, 2007. [PUBMED Abstract]
Scheuer L, Kauff N, Robson M, et al.: Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 20 (5): 1260-8, 2002. [PUBMED Abstract]
Botkin JR, Smith KR, Croyle RT, et al.: Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A 118 (3): 201-9, 2003. [PUBMED Abstract]